p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma

Journal of Investigative Dermatology

Volumn 122, Issue 5, 2004, Pages 1284-1292

  Brown, Victoria L ^a   Harwood, Catherine A ^a   Crook, Tim ^b   Cronin, James G ^a   Kelsell, David R ^a   Proby, Charlotte M ^a,c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Centre for Cutaneous Research   (United Kingdom)

Author keywords

CDKN2A; Cutaneous squamous cell carcinoma; Gene hyper methylation; p14ARF; p16INK4a; Tumor supressor genes

Indexed keywords

PROTEIN P14ARF; PROTEIN P16; PROTEIN P16INK4A;

AMINO ACID SUBSTITUTION; ARTICLE; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; GENE INACTIVATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; MARKER GENE; MUTATION RATE; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGY; MALE; METABOLISM; PATHOPHYSIOLOGY; SKIN TUMOR;

CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; POINT MUTATION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 2442566420     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.22501.x     Document Type: Article

References (48)

1. Alam M, Ratner D: Cutaneous squamous-cell carcinoma. N Engl J Med 344:975-983, 2001
2. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH: p14ARF links the tumour suppressors RB and p53. Nature 395:124-125, 1998
3. Bazan V, Zanna I, Migliavacca M, et al: Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma. J Cell Physiol 192:286-293, 2002
4. Bertram CG, Gaut RM, Barrett JH, et al: An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 119:961-965, 2002
5. Brash DE, Rudolph JA, Simon JA, et al: A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128, 1991
6. Esteller M, Cordon-Cardo C, Corn PG, et al: p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61:2816-2821, 2001a
7. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229, 2001b
8. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60:129-133, 2000
9. Fargnoli MC, Chimenti S, Keller G, Soyer HP, Dal Pozzo V, Hofler H, Peris K: CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. J Invest Dermatol 111:1202-1206, 1998
10. Gasco M, Bell AK, Heath V, et al: Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: Association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 62:2072-2076, 2002
11. Grossman D, Leffell DJ: The molecular basis of nonmelanoma skin cancer: New understanding. Arch Dermatol 133:1263-1270, 1997
12. Harwood CA, Proby CM: Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 15:101-114, 2002
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826, 1996
14. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DMA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995
15. Holme SA, Malinovszky K, Roberts DL: Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 143:1224-1229, 2000
16. Huang MJ, Yeh KT, Shih HC, et al: The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. Int J Mol Med 10:551-554, 2002
17. Johnson TM, Rowe DE, Nelson BR, Swanson NA: Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 26: 467-484, 1992
18. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
19. Kamijo T, Zindy F, Roussel MF, et al: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659, 1997
20. Koh J, Enders GH, Dynlacht BD, Harlow E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510, 1995
21. Kubo Y, Urano Y, Matsumoto K, Ahsan K, Arase S: Mutations of the INK4a locus in squamous cell carcinomas of human skin. Biochem Biophys Res Commun 232:38-41, 1997
22. Kushida Y, Miki H, Ohmori M: Loss of heterozygosity in actinic keratosis, squamous cell carcinoma and sun-exposed normal-appearing skin in Japanese: Difference between Japanese and Caucasians. Cancer Lett 140:169-175, 1999
23. Lee YY, Kang SH, Seo JY, et al: Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. Cancer 80:1889-1896, 1997
24. Liggett WH Jr, Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16:1197-1206, 1998
25. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS: Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143:513-519, 2000
26. Martinez JC, Otley CC, Stasko T, Euvrard S, Brown C, Schanbacher CF, Weaver AL: Defining the clinical course of metastatic skin cancer in organ transplant recipients: A multicenter collaborative study. Arch Dermatol 139:301-306, 2003
27. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG: In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96:12754-12759, 1999
28. Okabe H, Ikai I, Matsuo K, et al: Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology 31:1073-1079, 2000
29. Parry D, Peters G: Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16:3844-3852, 1996
30. Peng CY, Chen TC, Hung SP, et al: Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. Anticancer Res 22:1265-1271, 2002
31. Peris K, Stanta G, Fargnoli MC, Bonin S, Felli A, Amantea A, Chimenti S: Reduced expression of CDKN2a/P16INK4a in mycosis fungoides. Arch Dermatol Res 291:207-211, 1999
32. Pollock PM, Pearson JV, Hayward NK: Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chromosomes Cancer 15:77-88, 1996
33. Quinn AG, Sikkink S, Rees JL: Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 54:4756-4759, 1994a
34. Quinn AG, Sikkink S, Rees JL: Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers. Genes Chromosomes Cancer 11:222-225, 1994b
35. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN: Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 147:950-956, 2002
36. Ranade K, Hussussian CJ, Sikorski RS, et al: Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114-116, 1995
37. Reed AL, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS-1/ INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633, 1996
38. Rehman I, Quinn AG, Takata M, Taylor AEM, Rees JL: Low frequency of allelic loss in skin tumors from immunosupressed individuals. Br J Cancer 76:757-759, 1997
39. Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF: Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276:41424-41434, 2001
40. Sanchez-Cespedes M, Reed AL, Buta M, et al: Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 18:5843-5849, 1999
41. Saridaki Z, Liloglou T, Zafiropoulos A, Koumantaki E, Zoras O, Spandidos DA: Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin. Br J Dermatol 148:638-648, 2003
42. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993
43. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37, 1996
44. Sharpless NE, Bardeesy N, Lee KH, et al: Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413:86-91, 2001
45. Soufir N, Moles JP, Vilmer C, et al: P16 UV mutations in human skin epithelial tumors. Oncogene 18:5477-5481, 1999
46. Stone S, Jiang P, Dayananth P, et al: Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988-2994, 1995
47. Stott FJ, Bates S, James MC, et al: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001-5014, 1998
48. Zhang Y, Xiong Y: Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 3:579-591, 1999